Exponential Growth 2021 to Date | One of Europe's leading biopharmaceutical companies

Every now and then, New Scientist helps a carefully selected commercial partner speak to our audience. Their support helps us produce the high quality journalism we bring you every week. We hope you find today's message relevant and useful. Opportunity to invest in GROWTM One of Europe’s leading biopharmaceutical companies specialising in cannabis-based medicines [Grow Group Image]( Want to speak with one of our team? [Click Here]( to organise a call Why GROW now? Exponential Growth 2021 to Date - Vertically integrated medical cannabis company with ambitions to be a global leader - Grow Pharma now profitable in the UK - Revenues already over £3.5m million for 2021 - Grow doubled in revenue between 2019 and 2020, and doubled again by June 2021 - Exclusive UK distribution partnerships with global leading brands including Tilray and Columbia Care - Expanding domestically and internationally - Recently acquired Sanoid, one of the first licensed Cannabis production facilities in Spain, capable of producing up to 20 tons of medical cannabis a year. - Proprietary cannabis technologies under 100% owned patents which deliver on low-cost and high-quality cannabinoids. [As Seen In]( To invest today [Click Here]( Investment will help us continue to unlock the potential of cannabis medicines Our goal is to be the world's largest provider of medical cannabis by patient numbers by 2025. [Ben Langley, CEO]( Ben Langley, CEO "The patient is at the heart of everything we do. Our company is promising to deliver on this by making affordable and accessible cannabis medicines available to all." We have a £6m round open of which over £4m has been raised. Funding will be used for: - Expansion into Germany - Commercialisation of our patented R&D technologies - Capital expenditure into processing and extraction facility in Spain Meet the team behind getting patients access to cannabis-based medicines. [Click Here]( [Grow Group Logo]( Disclaimer: Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Investment is only available to High-Net-Worth Investors or Sophisticated Investors. Please remember that financial investments may rise or fall, and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested. You should always seek advice from a regulated financial advisory before making any investment. * This email has been sent to {EMAIL} * [Unsubscribe]( from further emails relating to selected third party partners from New Scientist. * Read our [privacy policy]( Disclaimer This message is intended only for the use of the person(s) ("Intended Recipient") to whom it is addressed. It may contain information, which is privileged and confidential. Accordingly any dissemination, distribution, copying or other use of this message or any of its content by any person other than the Intended Recipient may constitute a breach of civil or criminal law and is strictly prohibited. If you are not the Intended Recipient, please contact the sender as soon as possible. We and our third party service providers may use cookies and other web technologies in conjunction with this email. These technologies are used to understand activity with this email and on certain portions of our website. This enables us to improve our site, your experience on our site, and the offerings that we may provide to you. If you do not want these technologies placed on your device, please opt-out of receiving emails from us. New Scientist Ltd Registered Office: 25 Bedford Street, London, WC2E 9ES Registered in England under Company No. 10644366 Australian Office: Suite 3, Level 11, 100 Walker Street, North Sydney NSW 2060 Registered in Australia under ABN 22 621 413 170